Dart Neuroscience
Dart NeuroScience LLC is a neuroscience-focused drug-discovery organization established in San Diego. The company concentrates on identification and validation of gene targets underlying memory and cognitive processes, discovery and optimization of small-molecule modulators (including programs targeting phosphodiesterase 4, monoamine oxidase B, GlyT1, and GABA-A), preclinical evaluation in animal models, and early-phase clinical development. The organization supports external research collaborations and transfers programs and assets to interested parties.
Industries
Nr. of Employees
large (251-1000)
Dart Neuroscience
San Diego, California, United States, North America
Patents
Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as PDE2 inhibitors
US-12630556-B2
View Details
Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as PDE2 inhibitors
US-12630556-B2
View DetailsProducts
PDE4 inhibitor programs for memory enhancement
Small-molecule PDE4 inhibitor programs developed to elevate cAMP/CREB signaling and enhance long-term memory; early clinical studies reported (Phase 1 and Phase 2a).
MAO-B inhibitor clinical program
Highly selective reversible MAO-B inhibitor program designed to elevate dopaminergic signaling for potential memory enhancement; in-house clinical studies underway.
GlyT1 inhibitor preclinical program
Glycine transporter-1 (GlyT1) inhibitor program discovered via transcriptional profiling during memory formation; lead in preclinical development with CMC/IND planning.
GABA-A inverse agonist discovery
Discovery efforts focused on highly selective GABA-A inverse agonists as modulators of cognitive function.
Novel 'plasticity modulator' discovery programs
Multiple first-in-class discovery projects (candidate memory genes) targeting mechanisms that regulate synaptic plasticity and memory; several leads in preclinical development or lead-optimization.
PDE4 inhibitor programs for memory enhancement
Small-molecule PDE4 inhibitor programs developed to elevate cAMP/CREB signaling and enhance long-term memory; early clinical studies reported (Phase 1 and Phase 2a).
MAO-B inhibitor clinical program
Highly selective reversible MAO-B inhibitor program designed to elevate dopaminergic signaling for potential memory enhancement; in-house clinical studies underway.
GlyT1 inhibitor preclinical program
Glycine transporter-1 (GlyT1) inhibitor program discovered via transcriptional profiling during memory formation; lead in preclinical development with CMC/IND planning.
GABA-A inverse agonist discovery
Discovery efforts focused on highly selective GABA-A inverse agonists as modulators of cognitive function.
Novel 'plasticity modulator' discovery programs
Multiple first-in-class discovery projects (candidate memory genes) targeting mechanisms that regulate synaptic plasticity and memory; several leads in preclinical development or lead-optimization.
Services
Funding and management of academic and external research projects in neuroscience to support identification and validation of memory-related targets.
Transfer, licensing, or sale of internal drug discovery programs and related assets to interested parties.
Collaborative preclinical pharmacology, DMPK, and lead optimization support for CNS drug programs.
Funding and management of academic and external research projects in neuroscience to support identification and validation of memory-related targets.
Transfer, licensing, or sale of internal drug discovery programs and related assets to interested parties.
Collaborative preclinical pharmacology, DMPK, and lead optimization support for CNS drug programs.
Expertise Areas
- Memory disorder drug discovery
- Preclinical pharmacology and behavioral neuroscience
- High-throughput screening and assay development
- Medicinal chemistry and lead optimization
Key Technologies
- High-throughput screening (cell-based reporter assays)
- LC-MS/MS bioanalysis
- In vivo behavioral assays (rodent and primate)
- Recombinant GPCR expression optimization (virus-like particles)
News & Updates
Dart NeuroScience LLC opened operations in San Diego on August 7, 2008.
Multiple scientific articles authored or co-authored by company scientists covering PDE inhibitors, GlyT1 inhibitors, MAO-B inhibitors, LC-MS/MS methods, and related topics (selected list on publications page).
Dart NeuroScience LLC opened operations in San Diego on August 7, 2008.
Multiple scientific articles authored or co-authored by company scientists covering PDE inhibitors, GlyT1 inhibitors, MAO-B inhibitors, LC-MS/MS methods, and related topics (selected list on publications page).